|
|
Article: AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies.
- Article from:
- PR Newswire
- Article date:
- November 6, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, November 6 /PRNewswire-FirstCall/ -- AIM-quoted drug discovery company Verona Pharma is pleased to announce another important step forward in the planned development of its anti-asthma and hay fever drug treatment.
The Company's novel anti-asthmatic compound, RPL554, is now entering a second 28-day experimental inhalation toxicology study in another species in order to demonstrate safety, before moving onto the proof of concept clinical trials early next year.
RPL554 is a long-acting bronchodilator/anti-inflammatory molecule being developed to treat hay fever (rhinitis), asthma and chronic obstructive pulmonary disease. A significant feature of ...